ZMYND11 and prostate carcinoma: We proceeded to examine the impact of ZMYND11 on prostate cancer tumor cellular phenotypes and invasiveness by conducting knockdown assays using lentivirus-mediated short hairpin RNA (shRNA) or synthetic small interfering RNA (siRNA) against ZMYND11 in several prostate cancer cell models (Fig. 2a and Supplementary Fig. 2a).